Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
“PT-141 Research Peptide” has been added to your cart. View cart
SOLD OUT
CJC-1295 No DAC Research Peptide
£25.00
🔬 RESEARCH USE ONLY — This product is strictly for laboratory research and educational purposes. Not for human or veterinary use.
CJC-1295 No DAC Research Peptide (10–40 mg, ≥98% purity, CAS 876168-09-9) — Modified GRF 1–29 for GHRH receptor activation & pulsatile GH secretion studies. RUO, CoA-backed, UK dispatch. Recommended products for reconstitution will be automatically added to the cart → Adjust quantities before checkout.
CJC-1295 No DAC (Modified GRF 1–29) is a synthetic, 29-amino-acid analogue of growth hormone-releasing hormone (GHRH), engineered to investigate pulsatile GH secretion, somatotrope sensitivity, and GHRH receptor (GHRHR) signalling dynamics. It has become a pivotal compound in preclinical endocrinology, muscle metabolism, and receptor pharmacology research due to its enhanced stability over native GRF and clean pharmacokinetic profile (no albumin-binding DAC moiety). This CJC-1295 No DAC research peptide is supplied as a lyophilised solid to ensure structural integrity, purity, and reproducibility in laboratory and investigative settings.
Supplied in lyophilised (freeze-dried) form to preserve stability.
What is the CJC-1295 No DAC Research Peptide?
CJC-1295 No DAC (C₁₅₂H₂₅₄N₄₄O₄₂, MW: 3367.95 g/mol) is a modified GRF(1–29) analogue with four key substitutions (Ala² → D-Ala², Asp⁸ → Glu⁸, Ala¹⁵ → Leu¹⁵, Gly²⁷ → Ala²⁷) and C-terminal amidation, conferring resistance to dipeptidyl peptidase-4 (DPP-4) degradation [Veldhuis JD et al., J Clin Endocrinol Metab 2007; 92(3):957–964; DOI: 10.1210/jc.2006-2115]. Unlike DAC-containing variants, this No DAC form lacks the lysine-based drug affinity complex (DAC), resulting in a shorter half-life (~30 min in rodents) ideal for pulsatility studies. Supplied exclusively for in vitro, ex vivo, and preclinical research — not for human or veterinary use.
🔬 Note: CJC-1295 No DAC is distinct from CJC-1295 with DAC (CAS 876168-10-2). This RUO material is unformulated, preservative-free, and intended solely for GHRH receptor pharmacology and GH pulse dynamics research.
Scientific Identifiers
Field
Value
Product Name
CJC-1295 No DAC (Modified GRF 1–29) Research Peptide
The CJC-1295 No DAC research peptide is supplied freeze-dried for stability. For experimental protocols, reconstitute using: ✅ Sterile bacteriostatic water (0.9% benzyl alcohol in 0.9% NaCl), or ✅ 0.1% acetic acid in sterile saline — recommended for solubility (hydrophobic residues).
⚠️ Critical Handling Notes: – Gentle warming (≤37°C) and brief sonication may aid dissolution. – Avoid vigorous vortexing — may promote aggregation of hydrophobic core (Phe⁶, Leu¹⁵, Leu²²). – Filter through 0.22 µm PVDF for cell-based assays.
Post-Reconstitution Storage: – Short-term: 2–8°C for ≤72 hours – Long-term: Aliquot and store at −80°C (≤3 freeze–thaw cycles)
🛒 Recommended reconstitution accessories will be auto-added to cart → Adjust before checkout.
CJC-1295 No DAC Research Peptide: Key Investigational Pathways
CJC-1295 No DAC is actively studied for its clean GHRH receptor activation. Key research applications include:
GHRH Receptor Pharmacology
Investigated in:
→ HEK293 cells stably expressing hGHRHR for cAMP, IP₁, and β-arrestin bias profiling
→ Competitive binding vs. native GRF(1–44) and Tesamorelin
→ Receptor internalisation kinetics (SNAP-tag confocal imaging)
📚 Research-first ethos: No “HGH booster” or performance claims — full support for receptor pharmacology
🛡️ RUO integrity: Meets MHRA GMP Guide, FDA 21 CFR 1271, EU Annex 1 expectations
💬 Expert support: Get help with pulse dosing protocols, cAMP/β-arrestin assay design, or pituitary cell culture
Legal and Safety Information
NovaVitality supplies CJC-1295 No DAC strictly for laboratory research, assay development, and educational purposes (RUO).
❌ This product is not approved by the MHRA, FDA, EMA, or any regulatory authority for: → Human use → Veterinary use → Diagnostic, therapeutic, or performance-enhancement use
⚠️ Critical Responsibilities for Researchers: – Use only under approved institutional biosafety protocols – Comply with local ethics oversight (e.g., AWERB for in vivo work) – Maintain full chain-of-custody documentation – Do not compound, dispense, or administer to living subjects
🔒 NovaVitality disclaims all liability for unauthorised or off-label use. By purchasing, you affirm compliance with all applicable laws and institutional policies.
Ready to Advance GHRH Receptor & GH Pulse Research?
